CVBF spotlight on scientific literature: “Why children have to wait years for new drugs”
This recent article is part of Nature Outlook: Children‘s health and focuses on the lack of medicines approved for paediatric use. According [...]
First gene therapy to treat haemophilia B
EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Hemgenix (etranacogene dezaparvovec), the the first gene therapy [...]
Event: The next steps for a real European Health Union – Delivering patient care through digital solutions
This in-person event, organized by the European Association of E-Pharmacies (EAEP) will be held on Thursday, 27 October at TownHall Europe (Square [...]
CVBF participates in the Smarter Programme For Technological Innovation
Thanks to the close collaboration with Aldo Moro University of Bari, Exprivia spa and Hero srl, and following the agreement signed with the [...]
CVBF September Special Issue
This new Special Issue is dedicated to the active involvement of CVBF in the European Joint Programme for Rare Diseases (EJP RD), [...]
Scientific publication: Patient-Reported Outcome Measures in Clinical Research
The “Patient-Reported Outcome Measures in Clinical Research” research paper describes the importance and also some limitations of the use of patient-reported outcome [...]